Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 03, 2023 08:45 ET | Source: Femasys Inc.

Femasys Initiates Enrollment in Pivotal Trial of its Permanent Birth Control Candidate FemBloc

ATLANTA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting women’s unmet needs worldwide by developing a broad portfolio of innovative product...
June 26, 2023 08:00 ET | Source: Femasys Inc.

Femasys Announces FDA Approval of its IDE for the Pivotal Clinical Trial of FemBloc Permanent Birth Control, a Non-Surgical Alternative for Women

- Pivotal clinical trial to begin in the third quarter of 2023 - ATLANTA, June 26, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women’s needs worldwide...
June 15, 2023 08:00 ET | Source: Femasys Inc.

Femasys Inc. Replaces Two Board Members with Seasoned Industry Leaders in the Life Sciences

-- Keith Kendall former President, COO and CFO of drug delivery company, Aquestive Therapeutics and Alistair Milnes COO of biotechnology company, Bicycle Therapeutics both join Femasys’ Board of...
June 14, 2023 08:00 ET | Source: Femasys Inc.

Femasys to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on June 20-22, 2023

ATLANTA, June 14, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs by developing a suite of products and product candidates that include...
June 08, 2023 08:30 ET | Source: Femasys Inc.

Femasys’ FemCath Intrauterine Catheter Receives Product Approval in Canada

-- FemCath® is the first intrauterine catheter that allows for selective evaluation of a fallopian tube with natural saline and air contrast -- -- FemCath is used in conjunction with Femasys’ FemVue®...
May 11, 2023 16:05 ET | Source: Femasys Inc.

Femasys Inc. Announces Financial Results for the First Quarter Ended March 31, 2023

-Received regulatory approval for both FemaSeed® and FemCerv® products from Health Canada- ATLANTA, May 11, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet...
May 11, 2023 08:30 ET | Source: Femasys Inc.

Femasys Inc. to Showcase Four Products at the American College of Obstetricians and Gynecologists Annual Clinic & Scientific Meeting

ATLANTA, May 11, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs by developing a suite of products and product candidates that include...
May 03, 2023 08:30 ET | Source: Femasys Inc.

Femasys’ FemCerv Endocervical Tissue Sampler for Cervical Cancer Diagnosis Receives Product Approval in Canada

- FemCerv® is the first endocervical tissue sampler designed to collect and contain a comprehensive sample to maximize quality and quantity - ATLANTA, May 03, 2023 (GLOBE NEWSWIRE) -- Femasys Inc....
May 01, 2023 16:05 ET | Source: Femasys Inc.

Femasys Inc. to Showcase FemCerv at the Annual Meeting for the American Society for Colposcopy and Cervical Pathology

ATLANTA, May 01, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs by developing a suite of products and product candidates that include...
April 19, 2023 08:00 ET | Source: Femasys Inc.

Femasys Announces $3.9 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

ATLANTA, April 19, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women’s needs by developing a suite of products and product candidates that include...